NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that the U.S. Patent and Trademark Office (USPTO) has posted on its Website a final rejection of CGPI’s patent application No. 10/757,656 covering a method of treating acne using chemically modified tetracyclines, including incyclinide. The notice does not state the reason for the rejection.
